NOVEL INHIBITOR OF BLOOD PLATELET AGGREGATION

PURPOSE:To obtain an inhibitor of blood platelet aggregation, having high safety and excellent effects, comprising N-2-(2-hydroxyethoxy)ethyl-N'-2,3,4- trimethoxybenzylpyrazine (acid addition salt) as an active ingredient. CONSTITUTION:The titled inhibitor containing a compound (n2-TMZ) shown by the formula having pharmaceutical action on coronary cardiovascular system such as suppression of erethism of heart motion or suppression of coronaria blood vessel. The inhibitor is effective against thrombosis such as cerebral infarct, cerebral thrombosis and myocardial infarction and diseases such as disseminated intravascular coagulation syndrome, etc. A dose is usually 20-200 mg/time (administered twice daily) calculated as n2-TMZ in the case of oral administration and is 1/3 the dose of the oral administration in the case of parenteral administration. n2-TMZ has a little lower inhibitory action on aggregation of arachidonic acid than that of acetylsalicylic acid but causes no gastrointestinal disorder resulting from continuous use of acetylsalicylic acid and can be used with another drug.